Christakis Christodoulou, MD
Interventional Cardiology · Pasadena, CANPI 1043396732
Payments from drug & device makers
Across 547 payments — averaging $124.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$23K
- Medtronic$23K
- Bayer$14K
- Abbott$2K
- Boston Scientific$850
- Amgen$667
- plus $5K from 38 others
What the payments were for
- Speaking & faculty fees$33,71249%
- Travel & lodging$13,53320%
- Food & beverage$20,62130%
- Education$2770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NORTHERA$22,279
- Adempas$14,241
- Micra$6,735
- Reveal LINQ$1,842
- TurboHawk$1,277
- VenaSeal$1,262
- LINQ II$1,136
- AVEIR$1,061
- EMBLEM MRI S-ICD$319
- Edwards SAPIEN 3 Transcatheter Heart Valve$252
- JOT DX$168
- COROFLOW$165
- SelectSecure$153
- SAPIEN 3 Ultra RESILIA$150
- FFRct$150
- Watchman$145
- Exogen$141
- AVVIGO Guidance System$141
- LUX-Dx Insertable Cardiac Monitor$137
- AREXVY$124
How this compares
$68,143 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 646 | $592,623 |
| XareltoRivaroxaban | 426 | $411,036 |
| JardianceEmpagliflozin | 269 | $289,119 |
| EntrestoSacubitril/Valsartan | 187 | $191,930 |
| Ambrisentan | 30 | $152,882 |
| FarxigaDapagliflozin Propanediol | 156 | $132,115 |
| OzempicSemaglutide | 89 | $128,061 |
| Repatha SureclickEvolocumab | 102 | $127,883 |
| MounjaroTirzepatide | 97 | $113,124 |
| RybelsusSemaglutide | 71 | $98,005 |
| BrilintaTicagrelor | 83 | $68,200 |
| LivaloPitavastatin Calcium | 89 | $42,658 |
| Nebivolol Hcl | 556 | $31,312 |
| TradjentaLinagliptin | 34 | $28,343 |
| MultaqDronedarone Hcl | 20 | $22,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $98 | $592,623646 claims |
| Johnson & JohnsonXarelto | $325 | $411,036426 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Glyxambi | $222 | $342,872327 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $221 | $245,334171 claims |
| AstraZenecaFarxiga, Brilinta | $267 | $200,315239 claims |
| NovartisEntresto | $355 | $191,930187 claims |
| Lilly USA, LLCMounjaro | $23 | $113,12497 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $64 | $52,104116 claims |
| MerckJanumet, Belsomra | $137 | $30,09029 claims |
| Sanofi-aventis U.S. LLCMultaq | $62 | $22,85820 claims |
| Esperion Therapeutics, Inc.Nexlizet | $48 | $21,59927 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $105 | $19,65440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Pasadena
- Nikhil DagaPasadena$421K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.